DiaMedica Therapeutics Inc. Price & Performance (DMAC)

DiaMedica Therapeutics saw its price target raised to $10 by a leading analyst, even as shares recently fell to $3.47. The company reported a quarterly loss, missing estimates by a cent. Despite short-term volatility and a downward trend, some analysts remain optimistic about the biotech’s pipeline and long-term growth prospects.123

DiaMedica Therapeutics is among over 50 firms advancing new therapies for moderate-to-severe chronic kidney disease and ischemic stroke. Recent FDA approvals and device clearances highlight competitive momentum in these therapeutic areas, with DM199 and other candidates progressing through clinical stages and attracting investor attention.45

DiaMedica Therapeutics has a market capitalization of about $151 million and 42.86 million shares outstanding. Insider ownership stands at nearly 39%, with institutions holding about 16%. The company’s shares have increased significantly year-over-year, reflecting ongoing capital activity and continued interest from both insiders and institutional investors.6